Isabelle Mahé/LinkedIn
Aug 1, 2025, 13:11
Isabelle Mahé Shares an Insight from APICAT Study: Use of Apixaban in Cancer Associated Thrombosis
Isabelle Mahé, University Professor, Hospital Practitioner in Internal Medicine, shared an insightful post on LinkedIn:
”APICAT Study : reduced dose of apixaban for extended treatment in patient with Cancer associated Thrombosis.
A practice changing study.”
Read the full article here.
Article: ”Apixaban for Cancer-Associated Venous Thromboembolism”
Authors: Zhuo Shao, Xinyu Zhai
Stay updated on the latest scientific advancements in the field of thrombosis with Hemostasis Today.
-
Feb 3, 2026, 15:11WFH: Latest News from the WHO Executive Board Session in Geneva
-
Feb 3, 2026, 14:54300 Million People, One Global Community – Rare Disease Day
-
Feb 3, 2026, 14:33Pedro Henrique Las Casas: VTE After BCMA Directed CAR T-Cell Therapy in Multiple Myeloma
-
Feb 3, 2026, 14:26Anuoluwapo Babalola։ What The U.S. Exit from WHO Means for Global Health Leadership
-
Feb 3, 2026, 14:16Michiel Voet: Why Every Military Should Have a Dedicated Blood Unit
-
Feb 3, 2026, 10:53Aurelio Maggio: The Final Chapter of Our Journey Through Thalassemia
-
Feb 3, 2026, 10:40Pedro Perez: Post-Thrombectomy DVT Recovery in 2026 – Closing the Loop on Outcomes
-
Feb 3, 2026, 10:26Ryan Williams: This Article Brings to Light The Complexity of PRP…
-
Feb 3, 2026, 10:05Tiago Lopes: Can AI Predict Immune Reactions of New Drugs? Yes!